Borosil Scientific Limited
CIN : L74999MH1991PLC061851
Registered & Corporate Office
1101, Crescenzo, G-Block, Opp. MCAClub, Bandra Kurla Complex,
Bandra(E), Mumbai-400 051, India
T +91 22 6740 6300
F +91 22 6740 6514
E bsl@borosil.com
W www.borosilscientific.com

August 03, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: **544184**

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra-Kurla Complex,
Bandra (East), Mumbai 400 051

Trading Symbol: **BOROSCI**

Dear Sirs,

Sub: Outcome of the Board Meeting

In furtherance of our intimation dated July 27, 2026, we hereby inform you that the Board of Directors of the Company at its meeting held today, i.e. August 03, 2026, has, *inter alia*, considered and approved the following:

(a) Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.

The aforesaid Financial Results along with Limited Review Reports of the Statutory Auditor are attached and are also made available on the Company's website at Financial Results - Borosil Scientific.

(b) Modifications / amendments to the Company's ESOP schemes viz. (i) Borosil Scientific Limited – Special Purpose Employee Stock Option Plan 2023 ("**SP-ESOP 2023**") and (ii) Borosil Scientific Limited – Employee Stock Option Scheme ("**BSL ESOS**"), in accordance with the provisions of the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 and the Companies Act, 2013, based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the Members of the Company and other regulatory / statutory approvals as may be necessary.

The aforesaid ESOP schemes are being amended mainly for following purposes:

- To arrange shares for Employee Stock Option ("**Options**") holders upon exercise of Options, either from primary issuance or secondary acquisition through Trust route. Currently, the Company directly allots shares to Options holders by way of primary issuance. (**for both Schemes**).
- To increase the maximum limit of discount percentage for grant of new Options from existing 10% to 20% to the closing market price of shares one day prior to the date of grant of options (**for BSL ESOS**).

The meeting of the Board of Directors commenced at 3:10 p.m. (IST) and concluded at 4:15 p.m. (IST).

Yours faithfully,

For **Borosil Scientific Limited**

RAMAVTAR RAMNIWAS SHARMA
Digitally signed by RAMAVTAR RAMNIWAS SHARMA
Date: 2026.08.03 17:43:37 +05'30'

Ramavtar Sharma
Company Secretary & Compliance Officer

Independent Auditor's Review Report on Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

The Board of Directors of
Borosil Scientific Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Borosil Scientific Limited** ("the Company") for the quarter 30th June 2026 ("the statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulation"), as amended.

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making enquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we don't express an audit opinion.

CHATURVEDI & SHAH LLP
CHARTERED ACCOUNTANTS
MUMBAI

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi & Shah LLP
Chartered Accountants
Registration No. 101720W/W100355

Anuj Bhatia
Partner
Membership No. 122179
UDIN No: 26122179PYJPZX1805

CHATURVEDI & SHAH LLP MUMBAI CHARTERED ACCOUNTANTS

Place: Mumbai
Date: 03rd August, 2026

BOROSIL SCIENTIFIC LIMITED

CIN: L74999MH1991PLC061851

Regd. Office : 1101, 11th floor, Crescenzo, G-Block, Plot No.C-38, Opp. MCA Club, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Tel.No.(022) 67406300 Fax No.(022) 67406514 Website : www.borosilscientific.com Email : bsl@borosil.com

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(Rs. in lakhs except as stated)

S. No.	Particulars	Standalone			
		Quarter ended			Year ended
		(30/06/2026)	(31/03/2026)	(30/06/2025)	(31/03/2026)
I.	**Income:**				
	Revenue From Operations	9,989.68	13,191.95	8,900.95	42,753.08
	Other Income	279.62	212.27	306.04	1,018.42
	Total Income (I)	**10,269.30**	**13,404.22**	**9,206.99**	**43,771.50**
II.	**Expenses:**				
	Cost of Materials Consumed	3,896.58	4,174.47	3,065.53	14,486.60
	Purchases of Stock-in-Trade	39.17	250.64	148.70	596.29
	Changes in Inventories of Work-in-progress, Finished Goods and Stock-in-trade	(869.06)	216.26	(125.12)	(145.70)
	Employee Benefits Expense	1,795.05	1,557.64	1,565.30	6,453.05
	Finance Costs	10.45	5.81	18.19	42.12
	Depreciation and Amortization Expense	444.91	431.62	446.68	1,752.11
	Other Expenses	4,021.09	3,883.01	3,360.15	14,359.63
	Total Expenses (II)	**9,338.19**	**10,519.45**	**8,479.43**	**37,544.10**
III.	**Profit Before Exceptional Items and Tax (I - II)**	**931.11**	**2,884.77**	**727.56**	**6,227.40**
IV.	Exceptional Items (Refer Note 2)	-	-	661.31	852.82
V.	**Profit Before Tax (III - IV)**	**931.11**	**2,884.77**	**66.25**	**5,374.58**
VI.	**Tax Expense:**				
	(1) Current Tax	175.48	738.08	-	1,441.35
	(2) Deferred Tax	71.28	(6.88)	20.49	(39.23)
	Total Tax Expenses	**246.76**	**731.20**	**20.49**	**1,402.12**
VII.	**Profit for the Period / Year (V - VI)**	**684.35**	**2,153.57**	**45.76**	**3,972.46**
VIII.	**Other Comprehensive Income (OCI)** **Items that will not be reclassified to profit or loss:**				
	a) Re-measurement gains / (losses) on defined benefit plans	(8.41)	(73.58)	2.47	(61.35)
	b) Income tax effect on above	2.12	18.52	(0.62)	15.44
	Total Other Comprehensive Income	**(6.29)**	**(55.06)**	**1.85**	**(45.91)**
IX.	**Total Comprehensive Income for the Period / Year (VII + VIII)**	**678.06**	**2,098.51**	**47.61**	**3,926.55**
X.	**Paid-up Equity Share Capital (Face value of Re. 1/- each fully paid up)**	889.47	889.47	889.46	889.47
XI.	**Other Equity excluding Revaluation Reserve**				44,190.79
XII.	**Earning per equity share (in Rs.) (Face value of Re. 1/- each)**				
	Basic (Not Annualised)*	0.77*	2.42 *	0.05 *	4.47
	Diluted (Not Annualised)*	0.77*	2.42 *	0.05 *	4.47

CHATURVEDI & SHAH LLP MUMBAI CHARTERED ACCOUNTANTS

BOROSIL SCIENTIFIC LIMITED

BOROSIL SCIENTIFIC LIMITED

UNAUDITED STANDALONE SEGMENT INFORMATION FOR THE QUARTER ENDED 30TH JUNE, 2026

(Rs. in lakhs)

S. No.	Particulars	Standalone			
		Quarter ended			Year ended
		(30/06/2026)	(31/03/2026)	(30/06/2025)	(31/03/2026)
1	**Segment Revenue :**				
	a. Scientific – Laboratory Glass & equipment and Process System	5,982.56	9,844.79	5,625.81	29,155.68
	b. Glassware	3,836.21	3,166.62	3,213.12	13,035.52
	c. Others	170.91	180.54	62.02	561.88
	Total	**9,989.68**	**13,191.95**	**8,900.95**	**42,753.08**
	Less : Inter Segment Revenue	-	-	-	-
	Revenue from operations	**9,989.68**	**13,191.95**	**8,900.95**	**42,753.08**
2	**Segment Results (Profit before tax):**				
	a. Scientific – Laboratory Glass & equipment and Process System	1,253.56	3,365.14	1,306.42	8,616.39
	b. Glassware	19.00	(172.63)	(240.26)	(1,156.58)
	c. Others	42.97	48.70	23.92	205.89
	Total	**1,315.53**	**3,241.21**	**1,090.08**	**7,665.70**
	Less:- Finance Cost	10.45	5.81	18.19	42.12
	Less: Exceptional Items (Refer Note 2)	-	-	661.31	852.82
	Less:- Other unallocable expenditure (net of income)	373.97	350.63	344.33	1,396.18
	Profit before tax	**931.11**	**2,884.77**	**66.25**	**5,374.58**
3	**Segment Assets**				
	a. Scientific – Laboratory Glass & equipment and Process System	15,349.95	16,730.07	13,976.34	16,730.07
	b. Glassware	12,764.58	12,191.40	10,805.16	12,191.40
	c. Others	336.64	350.94	194.23	350.94
	d. Un-allocated	26,999.25	25,650.20	24,194.54	25,650.20
	Total	**55,450.42**	**54,922.61**	**49,170.27**	**54,922.61**
4	**Segment Liabilities**				
	a. Scientific – Laboratory Glass & equipment and Process System	4,844.86	4,988.05	3,321.28	4,988.05
	b. Glassware	2,281.42	2,439.00	2,050.66	2,439.00
	c. Others	82.25	53.36	17.03	53.36
	d. Un-allocated	1,350.92	1,263.65	1,636.08	1,263.65
	Total	**8,559.45**	**8,744.06**	**7,025.05**	**8,744.06**

Note :

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Company has reported "Segment information", as described below:

Scientific – Laboratory Glass & equipment and Process System:- Comprising of items used in laboratories, production floor and research and development

Glassware:- Pharmaceutical primary packaging and domestic glassware items

Others :- Comprising of Filter Paper etc.

Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.

CHATURVEDI & SHAH MUMBAI CHARTERED ACCOUNTANTS

BOROSIL SCIENTIFIC LIMITED

BOROSIL Scientific

Borosil Scientific Limited

CIN : L74999MH1991PLC061851
Registered & Corporate Office
1101, Crescenzo, G-Block, Opp. MCAClub, Bandra Kurla Complex,
Bandra(E), Mumbai-400 051, India
T +91 22 6740 6300
F +91 22 6740 6514
E bsl@borosil.com
W www.borosilscientific.com

Notes on Unaudited Standalone Financial Results for the quarter ended 30th June, 2026:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 3rd August, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the above results.

2. Exceptional items comprise: i) Rs. 661.31 lakhs for the quarter ended 30th June, 2025 and the year ended 31st March, 2026, representing expenditure incurred towards the Voluntary Retirement Scheme (VRS) for eligible workers at the Company's plant located at Village Ambad, Nashik, Maharashtra and ii) Rs. 191.51 lakhs for the year ended 31st March, 2026, representing the one-time incremental impact arising from the implementation of the new Labour Codes.

3. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable. The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures of the full financial year and the published year to date figures upto the third quarter of the respective financial year.

For **Borosil Scientific Limited**

BOROSIL SCIENTIFIC LIMITED

Place: Mumbai
Date : 3rd August, 2026

Vinayak Patankar
Whole-time Director & CEO
(DIN 07534225)

CHATURVEDI & SHAH LLP
MUMBAI
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

The Board of Directors of
Borosil Scientific Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Borosil Scientific Limited** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together refer to as "the Group") for the quarter ended 30^{th} June, 2026 ("the statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("the Listing Regulation"), as amended.

2. This statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making enquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently

CHATURVEDI & SHAH LLP
MUMBAI
CHARTERED ACCOUNTANTS

does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we don't express an audit opinion.

We also performed procedures in accordance with the circular no. CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, as amended, to the extent applicable.

4. The statement includes the results of its subsidiary Goel Scientific Glass Works Limited.

5. Based on our review conducted as above and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The unaudited consolidated financial result includes the interim financial results of 1 subsidiary, whose interim financial results reflect total revenue of Rs. 762.82 Lakhs, total net profit/(loss) after tax of Rs. (236.18) Lakhs and total comprehensive income of Rs. (235.11) Lakhs for the quarter ended 30th June, 2026, as considered in the unaudited consolidated financial results. The interim financial results of the above subsidiary have been reviewed by other auditor, whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to amount and disclosures included in respect of that subsidiary is based solely on the report of the other auditor and procedures performed by us as stated in paragraph 3 above.

CHATURVEDI & SHAH LLP
MUMBAI
CHARTERED ACCOUNTANTS

Continuation sheet...

Our conclusion on the statement is not modified in respect of the above matter with respect to our reliance on the work done and report of the other auditor.

For Chaturvedi & Shah LLP
Chartered Accountants
Registration No. 101720W/W100355

Anuj Bhatia
Partner
Membership No. 122179
UDIN No: 26122179MJPXQL6505

Place: Mumbai
Date: 03rd August 2026

BOROSIL Scientific

BOROSIL SCIENTIFIC LIMITED

CIN: L74999MH1991PLC061851

Regd. Office : 1101, 11th floor, Crescenzo, G-Block, Plot No.C-38, Opp. MCA Club, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
Tel.No.(022) 67406300 Fax No.(022) 67406514 Website : www.borosilscientific.com Email : bsl@borosil.com

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(Rs. in lakhs except as stated)

S. No.	Particulars	Consolidated			
		Quarter ended			Year ended
		(30/06/2026)	(31/03/2026)	(30/06/2025)	(31/03/2026)
I.	**Income:**				
	Revenue From Operations	10,675.23	14,316.87	9,597.64	46,734.15
	Other Income	266.64	206.27	291.80	954.59
	Total Income (I)	**10,941.87**	**14,523.14**	**9,889.44**	**47,688.74**
II.	**Expenses:**				
	Cost of Materials Consumed	4,100.59	4,446.65	3,355.26	15,843.99
	Purchases of Stock-in-Trade	44.93	298.96	210.03	1,128.58
	Changes in Inventories of Work-in-progress, Finished Goods and Stock-in-trade	(813.62)	257.30	(109.49)	(288.44)
	Employee Benefits Expense	2,197.73	1,793.65	2,005.75	8,020.38
	Finance Costs	25.47	26.26	38.37	112.80
	Depreciation and Amortization Expense	488.73	476.22	487.62	1,923.88
	Other Expenses	4,299.97	4,309.50	3,648.79	15,810.27
	Total Expenses (II)	**10,343.80**	**11,608.54**	**9,636.33**	**42,551.46**
III.	**Profit before share of profit in associate, exceptional items and tax (I - II)**	**598.07**	**2,914.60**	**253.11**	**5,137.28**
IV.	Share of profit in associates	-	-	-	-
V.	**Profit before Exceptional Items and tax (III + IV)**	**598.07**	**2,914.60**	**253.11**	**5,137.28**
VI.	Exceptional Items (Refer Note 2)	-	-	661.31	852.82
VII.	**Profit / (Loss) Before Tax (V - VI)**	**598.07**	**2,914.60**	**(408.20)**	**4,284.46**
VIII.	**Tax Expense:**				
	(1) Current Tax	175.48	738.08	-	1,441.35
	(2) Deferred Tax	(12.92)	(548.07)	12.76	(615.01)
	Total Tax Expenses	**162.56**	**190.01**	**12.76**	**826.34**
IX.	**Profit / (Loss) for the Period / Year (VII - VIII)**	**435.51**	**2,724.59**	**(420.96)**	**3,458.12**
X.	**Other Comprehensive Income (OCI)**				
	Items that will not be reclassified to profit or loss:				
	a) Re-measurement gains / (losses) on defined benefit plans	(6.98)	(2.84)	(2.00)	(4.01)
	b) Income tax effect on above	1.76	0.72	0.50	1.01
	Total Other Comprehensive Income	**(5.22)**	**(2.12)**	**(1.50)**	**(3.00)**
XI.	**Total Comprehensive Income for the period / year (IX + X)**	**430.29**	**2,722.47**	**(422.46)**	**3,455.12**
XII.	**Profit / (Loss) attributable to:**				
	Owners of the Company	437.08	2,720.99	(416.43)	3,461.36
	Non-controlling interest	(1.57)	3.60	(4.53)	(3.24)
XIII.	**Other Comprehensive Income attributable to:**				
	Owners of the Company	(5.23)	(2.45)	(1.47)	(3.27)
	Non-controlling interest	0.01	0.33	(0.03)	0.27
XIV.	**Total Comprehensive Income attributable to:**				
	Owners of the Company	431.85	2,718.54	(417.90)	3,458.09
	Non-controlling interest	(1.56)	3.93	(4.56)	(2.97)
XV.	**Paid-up Equity Share Capital (Face value of Re. 1/- each fully paid up)**	889.47	889.47	889.46	889.47
XVI.	**Other Equity excluding Revaluation Reserve**				42,142.96
XVII.	**Earning per equity share (in Rs.) (Face value of Re. 1/- each)**				
	Basic (Not Annualised)*	0.49 *	3.06 *	(0.47) *	3.89
	Diluted (Not Annualised)*	0.49 *	3.06 *	(0.47) *	3.89

CHATURVEDI & SHAH LLP * CHARTERED ACCOUNTANTS * MUMBAI

BOROSIL SCIENTIFIC LIMITED

BOROSIL SCIENTIFIC LIMITED

UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER ENDED 30TH JUNE, 2026

(Rs. in lakhs)

S. No.	Particulars	Consolidated			
		Quarter ended			Year ended
		(30/06/2026)	(31/03/2026)	(30/06/2025)	(31/03/2026)
1	**Segment Revenue :**				
	a. Scientific – Laboratory Glass & equipment and Process System	6,668.11	10,960.75	6,311.97	33,092.96
	b. Glassware	3,836.21	3,175.58	3,223.65	13,079.31
	c. Others	170.91	180.54	62.02	561.88
	Total	**10,675.23**	**14,316.87**	**9,597.64**	**46,734.15**
	Less : Inter Segment Revenue	-	-	-	-
	Revenue from operations	**10,675.23**	**14,316.87**	**9,597.64**	**46,734.15**
2	**Segment Results (Profit /(Loss) before tax and non-controlling interests):**				
	a. Scientific – Laboratory Glass & equipment and Process System	935.54	3,406.12	838.89	7,544.17
	b. Glassware	19.00	(163.33)	(227.00)	(1,103.80)
	c. Others	42.97	48.70	23.92	205.89
	Total	**997.51**	**3,291.49**	**635.81**	**6,646.26**
	Less:- Finance Cost	25.47	26.26	38.37	112.80
	Less:- Exceptional Items (Refer Note 2)	-	-	661.31	852.82
	Less:- Other unallocable expenditure (net of income)	373.97	350.63	344.33	1,396.18
	Profit / (Loss) before Tax	**598.07**	**2,914.60**	**(408.20)**	**4,284.46**
3	**Segment Assets**				
	a. Scientific – Laboratory Glass & equipment and Process System	19,810.95	21,315.31	18,713.47	21,315.31
	b. Glassware	12,764.58	12,191.40	10,805.16	12,191.40
	c. Others	336.64	350.94	194.23	350.94
	d. Un-allocated	22,113.91	21,050.61	20,028.78	21,050.61
	Total	**55,026.08**	**54,908.26**	**49,741.64**	**54,908.26**
4	**Segment Liabilities**				
	a. Scientific – Laboratory Glass & equipment and Process System	6,058.06	6,267.75	5,106.61	6,267.75
	b. Glassware	2,281.42	2,439.00	2,050.66	2,439.00
	c. Others	82.25	53.36	17.03	53.36
	d. Un-allocated	1,990.44	1,998.89	2,450.67	1,998.89
	Total	**10,412.17**	**10,759.00**	**9,624.97**	**10,759.00**

Note :

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Group has reported "Segment information", as described below:

Scientific – Laboratory Glass & equipment and Process System:- Comprising of items used in laboratories, production floor and research and development

Glassware:- pharmaceutical primary packaging and domestic glassware items

Others :- Comprising of Filter Paper etc.

Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.

CHATURVEDI & SHAH LLP * CHARTERED ACCOUNTANTS * MUMBAI

BOROSIL SCIENTIFIC LIMITED

BOROSIL Scientific

Borosil Scientific Limited

CIN : L74999MH1991PLC061851
Registered & Corporate Office
1101, Crescenzo, G-Block, Opp. MCAClub, Bandra Kurla Complex,
Bandra(E), Mumbai-400 051, India
T +91 22 6740 6300
F +91 22 6740 6514
E bsl@borosil.com
W www.borosilscientific.com

Notes on Unaudited Consolidated Financial Results for the quarter ended 30th June, 2026:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 3rd August, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the above results.

2. Exceptional items comprise: i) Rs. 661.31 lakhs for the quarter ended 30th June, 2025 and the year ended 31st March, 2026, representing expenditure incurred towards the Voluntary Retirement Scheme (VRS) for eligible workers at the Company's plant located at Village Ambad, Nashik, Maharashtra and ii) Rs. 191.51 lakhs for the year ended 31st March, 2026, representing the one-time incremental impact arising from the implementation of the new Labour Codes.

3. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable. The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures of the full financial year and the published year to date figures upto the third quarter of the respective financial year.

For **Borosil Scientific Limited**

Vinayak Patankar
Whole-time Director & CEO
(DIN 07534225)

Place: Mumbai
Date : 3rd August, 2026

BOROSIL SCIENTIFIC LIMITED

CHATURVEDI & SHAH LLP
MUMBAI
CHARTERED ACCOUNTANTS